Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enoticumab, an antibody targeting DLL4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Demcizumab, an antibody targeting DLL4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vantictumab, an antibody targeting FZD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sofituzumab, an antibody targeting MUC16.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ralpancizumab, an antibody targeting PCSK9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vandortuzumab, an antibody targeting STEAP1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pasotuxizumab, an antibody targeting PSMA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Brontictuzumab, an antibody targeting NOTCH1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Laprituximab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Crotedumab, an antibody targeting GCGR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cergutuzumab, an antibody targeting CEACAM5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Afasevikumab, an antibody targeting IL-17A.